



Lenvatinib PI Recommendations¹



1. Lenvima® [package insert]. Nutley, NJ: Eisai Inc.

Proteinuria Management and Dose Adjustments for HCC

Management of Proteinuria



1. Protocol E7080-G000-304; 06 Jan 2014; Pages 8–11.
2. CSR E7080-G000-304; 24 May 2017; Pages 49–50.


Management of Proteinuria: Dose Reductions for Adverse Reactions

- Dose reductions occurred in succession based on the previous dose level

| | Recommended dose | First dosage reduction to | Second dosage reduction to | Third dosage reduction to | Fourth dosage reduction to |
|----------------------|------------------|---------------------------|----------------------------|---------------------------|----------------------------|
| Actual weight ≥60 kg | 12 mg once daily | 8 mg once daily | 4 mg once daily | 4 mg every other day | Discussed with Sponsor |
| Actual weight <60 kg | 8 mg once daily | 4 mg once daily | 4 mg every other day | Discussed with Sponsor | |

Proteinuria Management and Dose Adjustments for DTC

Management of Proteinuria



Management of Proteinuria: Dose Reductions for Adverse Reactions

- Dose reductions occurred in succession based on the previous dose level

| Recommended dose | First dosage reduction to | Second dosage reduction to | Third dosage reduction to | Fourth dosage reduction to |
|------------------|---------------------------|----------------------------|---------------------------|----------------------------|
| 24 mg once daily | 20 mg once daily | 14 mg once daily | 10 mg once daily | Discussed with Sponsor |

Eisai is unable to suggest individualized treatment approaches or provide advice or recommendations outside of the PI for the management of patients taking lenvatinib.